Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses

Cancer Research

Volumn 68, Issue 8, 2008, Pages 3010-3018

  Caserta, Stefano ^a,b,c   Alessi, Patrizia ^a   Guarnerio, Jlenia ^a   Basso, Veronica ^a   Mondino, Anna ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; INTERLEUKIN 2; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CELL FREE SYSTEM; CELL PROLIFERATION; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG METASTASIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL; TH2 CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, PROTOZOAN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; DROSOPHILA MELANOGASTER; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICE; MICE, INBRED BALB C; NEOPLASMS; PROTOZOAN PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 42349109325     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5796     Document Type: Article

References (45)

1. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
2. Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4(+) T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.
3. Benigni F, Zimmermann VS, Hugues S, et al. Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J Immunol 2005;175:739-48.
4. Topalian SL, Gonzales MI, Parkhurst M, et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996;183:1965-71.
5. Manici S, Sturniolo T, Imro MA, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11 [see comments]. J Exp Med 1999;189:871-6.
6. Pieper R, Christian RE, Gonzales MI, et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells [see comments]. J Exp Med 1999;189:757-66.
7. Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol 2006;176:5093-9.
8. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
9. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7.
10. Zimmermann VS, Casati A, Schiering C, et al. Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination. J Immunol 2007;179:2899-909.
11. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. Nat Med 1998;4:328-32.
12. Schultz ES, Schuler-Thurner B, Stroobant V, et al. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 2004;172:1304-10.
13. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
14. Casares N, Lasarte JJ, de Cerio AL, et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001;31:1780-9.
15. Miyazawa M, Fujisawa R, Ishihara C, et al. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J Immunol 1995;155:748-58.
16. Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol 2004;172:4215-24.
17. Banchereau J, Palucka AK, Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
18. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 2007;15:981-8.
19. Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods 2003;275:251-5.
20. Curtsinger J, Deeths MJ, Pease P, Mescher MF. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J Immunol Methods 1997;209:47-57.
21. Tham EL, Jensen PL, Mescher MF. Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins. J Immunol Methods 2001;249:111-9.
22. Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res 2004;10:76-83.
23. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9:619-24.
24. Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol 2003;106:16-22.
25. van Rensen AJ, Wauben MH, Grosfeld-Stulemeyer MC, van Eden W, Crommelin DJ. Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation. Pharm Res 1999;16:198-204.
26. Prakken B, Wauben M, Genini D, et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat Med 2000;6:1406-10.
27. Rogers J, Mescher MF. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen. J Immunol 1992;149:269-76.
28. Mescher MF, Savelieva E. Stimulation of tumor-specific immunity using tumor cell plasma membrane antigen. Methods 1997;12:155-64.
29. Goldberg J, Shrikant P, Mescher MF. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003;170:228-35.
30. Maus MV, Kovacs B, Kwok WW, et al. Extensive replicative capacity of human central memory T cells. J Immunol 2004;172:6675-83.
31. Malherbe L, Filippi C, Julia V, et al. Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with Leishmania major. Immunity 2000;13:771-82.
32. Murphy KM, Heimberger AB, Loh DY. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 1990;250:1720-3.
33. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003;63:3688-94.
34. Lucas B, Vasseur F, Penit C. Normal sequence of phenotypic transitions in one cohort of 5-bromo-2′-deoxyuridine-pulse-labeled thymocytes. Correlation with T cell receptor expression. J Immunol 1993;151:4574-82.
35. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994;171:131-7.
36. Bradley LM, Haynes L, Swain SL. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol 2005;26:172-6.
37. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-6.
38. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8(+) T cells. J Clin Invest 2005;115:1616-26.
39. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T-cell responses in different conditions of antigen exposure and persistence. J Immunol 2005;174:1037-45.
40. Zimmermann VS, Benigni F, Mondino A. Immune surveillance and anti-tumor immune responses: an anatomical perspective. Immunol Lett 2005;98:1-8.
41. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007;21:1859-74.
42. Mallone R, Nepom GT. MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin Immunol 2004;110:232-42.
43. Rudolf D, Silberzahn T, Walter S, et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother 2007;53:175-83.
44. Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007;179:4910-8.
45. Griffin MD, Hong DK, Holman PO, et al. Blockade of T-cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol 2000;164:4433-42.